









Immunotherapy progresses through the ages






New generation mAb structures

In vivo production of mAb by additive gene therapy







CRISPR-mediated gene engineering

A KO strategies

CSR from IgM to IgG1



Fab' fragment generation



B KI strategies

Expression of an sc Ig

